Technical Data
I7661-74Z
Interferon alpha 2 (alpha 2a), Recombinant, Human (Interferon alpha-2, IFN-alpha-2, IFNa2, IFNa2a, Interferon alpha-A, IFN-alphaA, IFNA, LeIF A, MGC125764, MGC125765)
100ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Recombinant protein corresponding to 165aa of human Interferon-alpha 2a expressed in E.coli is a single, non-glycosylated, polypeptide chain.

Biological Activity:
The specific activity as determined in a viral resistance assay using bovine kidney MDBK cells was found to be 2.7x10e8IU/mg.

Dimers and Aggregates:
<1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods:
1.UV spectroscopy at 280nm using the absorbency value of 0.924 as the extinctioncoefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of IFN-alpha(2a) as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~19.2kD
Source: E.coli
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005 Sep;12(5):473-80. 2. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005 Jun;14(2):109-15. 3. Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, andomized multicenter trial. Dig Dis Sci 2005 Jun;50(6):1148-55. 4. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. Oncol Rep 2005 Jun;13(6):1145-52. 5. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005 May;12(3):292-9. 6. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005 Feb;13(1):59-66.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.